0TB Stock Chart & Stats
€14.10
€0.10(1.14%)
At close: 4:00 PM EST
€14.10
€0.10(1.14%)
Day’s Range― - ―
52-Week Range€9.35 - €17.50
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€764.11M
Enterprise Value€510.89
Total Cash (Recent Filing)€394.67M
Total Debt (Recent Filing)€73.30M
Price to Earnings (P/E)7.4
Beta0.77
Next Earnings
Aug 05, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.26
Shares Outstanding51,828,255
10 Day Avg. Volume50
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)3.17
Price to Sales (P/S)8.76
P/FCF Ratio3.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.33Price Target Upside1.60% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)2.33
Revenue Forecast (FY)€96.64M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationTheravance’s shift to materially positive operating and free cash flow in 2025 and TTM, with free cash flow roughly matching net income, creates durable financial flexibility. This supports debt capacity, funding for R&D or restructurings, and value realization during strategic transactions.
Low Leverage / Improved Balance SheetA low-debt, positive-equity balance sheet provides resilience against funding shocks and enables strategic options (licensing, M&A, or payouts). The improved capital structure underpins ability to execute transactions and absorb restructuring costs without large refinancing risk.
Acquisition Provides Liquidity + Retained UpsideThe announced all-cash sale crystallizes shareholder value and provides immediate liquidity while the CVR preserves upside from ampreloxetine. The board’s unanimous approval and expected H2 2026 close increase certainty of value realization and reduce execution risk for shareholders.
Bears Say
Earnings Quality ConcernsReported profit is driven materially by non-operating items and one-offs rather than core operations. Negative EBIT despite positive net income indicates the operating business hasn’t delivered sustainable profitability, making future earnings vulnerable if one-time gains do not recur.
Modest Core Revenue GrowthLow single-digit organic revenue growth implies limited momentum in the core business and increases reliance on milestone, royalty, or transactional income. Sluggish top-line trends constrain long-term margin expansion and make operating leverage harder to achieve without new product wins or partner-driven upside.
Historical Volatility In Cash/equityPrior periods of negative equity and recent swings from cash burn to large inflows show underlying volatility. This history signals execution and model risk: improvements may reverse if expected milestones, partner payments, or deal proceeds are delayed or fail to materialize.
Theravance Biopharma News
0TB FAQ
What was Theravance Biopharma’s price range in the past 12 months?
Theravance Biopharma lowest stock price was €9.35 and its highest was €17.50 in the past 12 months.
What is Theravance Biopharma’s market cap?
Theravance Biopharma’s market cap is €764.11M.
When is Theravance Biopharma’s upcoming earnings report date?
Theravance Biopharma’s upcoming earnings report date is Aug 05, 2026 which is in 13 days.
How were Theravance Biopharma’s earnings last quarter?
Theravance Biopharma released its earnings results on May 07, 2026. The company reported -€0.088 earnings per share for the quarter, missing the consensus estimate of €0.025 by -€0.112.
Is Theravance Biopharma overvalued?
According to Wall Street analysts Theravance Biopharma’s price is currently Undervalued.
Does Theravance Biopharma pay dividends?
Theravance Biopharma does not currently pay dividends.
What is Theravance Biopharma’s EPS estimate?
Theravance Biopharma’s EPS estimate is 0.06.
How many shares outstanding does Theravance Biopharma have?
Theravance Biopharma has 51,828,255 shares outstanding.
What happened to Theravance Biopharma’s price movement after its last earnings report?
Theravance Biopharma reported an EPS of -€0.088 in its last earnings report, missing expectations of €0.025. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Theravance Biopharma?
Currently, no hedge funds are holding shares in DE:0TB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Theravance Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€14.33 (1.60% Upside)
€14.33 (1.60% Upside)
Blogger Sentiment
Bullish
DE:0TB Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth €5.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
48.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
37.47%
Trailing 12-Months
Company Description
Theravance Biopharma
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
0TB Stock 12 Month Forecast
Average Price Target
€14.33
▲(1.60% Upside)